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ARTICLE OPEN ACCESS
Development of a New Quality of Life Measure
for Duchenne Muscular Dystrophy Using Mixed
Methods
The DMD-QoL
Philip A. Powell, PhD, Jill Carlton, PhD, Donna Rowen, PhD, Fleur Chandler, MSc, Michela Guglieri, MD, and







Based on concerns about existing patient-reported outcome measures (PROMs) for assessing
quality of life (QoL) in Duchennemuscular dystrophy (DMD), we describe the mixedmethods
development of a new QoL PROM for use in boys and men with DMD: the DMD-QoL.
Methods
The DMD-QoL was developed in 3 stages. First, draft items were generated from 18 semi-
structured qualitative interviews with boys and men with DMD, analyzed using framework
analysis. Second, cognitive debriefing interviews with patients (n = 10), clinicians (n = 8), and
patients’ parents (n = 10) were undertaken, and a reduced item set was selected and refined.
Third, psychometric data on the draft items from a cross-sectional online survey (n = 102) and
stakeholder input from patients and patients’ parents were used to produce the final ques-
tionnaire. Patient and public involvement and engagement was embedded throughout the
process.
Results
From an initial draft of 47 items, a revised set of 27 items was produced at stage 2, and this set
was further refined at stage 3 to generate the DMD-QoL, a 14-item QoL PROM. The DMD-
QoL is designed for use from 7 years of age by proxy report and from 10 years of age by self-
report or proxy report. The final measure showed good psychometric properties.
Conclusion
TheDMD-QoL is a new 14-itemQoL PROM for boys andmen with DMD, with demonstrable
content and face validity.
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Studies assessing health-related quality of life (QoL) in people
with Duchenne muscular dystrophy (DMD) suggest that it is
impaired compared to the general population.1 However, the
ability of existing measures to adequately capture QoL in
DMD has been questioned,2 with it posited that there is no
optimal measure available.3 A recent systematic review of the
content and structural validity of QoL instruments used in
DMD highlighted that no measure had high-quality evidence
to support its use.4
Given the problems with existing measures, there is clear
justification for a new QoL patient-reported outcome mea-
sure (PROM) for use in people with DMD, developed with
demonstrable content validity. A further aim of the present
work was to produce a QoL measure that could be sub-
sequently adapted for use in the economic evaluation of DMD
health interventions via cost utility analysis.5 Specialized
preference-based PROMs are required for this purpose.
Existing, popular generic preference-based measures such as
the EQ-5D have been found to have poor content validity in
DMD,4 suggesting that there are no existing tools with proven
content validity that can be used to directly inform economic
health care resource allocation decisions in DMD.
Our primary objective was to develop a new QoL PROM for
use in boys and men with DMD (≥7 years of age) and to assess
its preliminary psychometric properties. The PROM has been
developed rigorously, across a series of sequential stages, in
accordance with best practice guidelines.6 Patient and public
involvement and engagement (PPIE) with patients and pa-
tients’ parents has been embedded throughout (figure 1).
Methods
The stages of development for the DMD-QoL are summa-
rized in figure 1 and in a published protocol.5We used amixed
methods PROM development design involving 3 stages:
qualitative interviewing (item generation), qualitative cogni-
tive debriefing interviews (item selection), and a cross-
sectional quantitative online survey (psychometric survey).
Standard Protocol Approvals, Registrations,
and Patient Consents
The research received ethics approval from the UK National
Health Service (NHS; REC reference: 18/SW/0055). Informed
consent was obtained from all participants (or guardians of
participants) in the study.
Stage 1: Item Generation
Items for the draft questionnaire were informed by semi-
structured interviews with 18 boys andmenwithDMD from the
United Kingdom between June 2018 and December 2018. Be-
cause we wanted to gain deeper insight into individuals’ expe-
riences of QoL, one-to-one interviews were preferred over focus
groups. The sample was purposively recruited with a sampling
grid (table 1) from 5 collaborating UK NHS sites (Alder Hey
Children’s NHS Foundation Trust, University Hospitals Bristol
NHS Foundation Trust, Leeds Teaching Hospitals NHS Trust,
Newcastle Upon Tyne Hospitals NHS Foundation Trust,
University College London Hospitals NHS Foundation Trust),
the charity Duchenne UK, and a patient support group (DMD
Pathfinders). Eligibility criteria consisted of a confirmed (NHS
Trusts) or self-disclosed (Duchenne UK/DMD Pathfinders)
diagnosis of DMD.Multiple sources of recruitment were used to
try to obtain as broad a participation as possible.
Recruitment continued until data saturation was reached (no
new themes emerged in the interviews), which was sooner than
anticipated in the study protocol5 and encompassed a breadth of
age and clinical characteristics (table 1). Participants were
interviewed either face-to-face or online (via Skype) for a mean
length of 53 minutes (SD 15 minutes) with a flexible approach
adopted to help people participate in their preferred medium.
A topic guide (available online: doi.org/10.15131/shef.data.
12942998.v1, file A) was developed to cover aspects of QoL
known to be potentially relevant to DMD1 and was endorsed by
PPIE representatives at Duchenne UK. As part of the interview,
participants were shown examples of generic PROMs commonly
used in cost-utility analyses (i.e., EQ-5D or EQ-5D-Y,7,8 Health
Utilities Index,9,10 and/or Child Health Utility–9D11) and asked
for their opinions on them, including their comprehensiveness.
Interviews were conducted by a chartered psychologist with
experience in qualitative research and conducting research in-
terviews. The interviewer was not known to the participants
before the study. While the interviewer had knowledge of QoL
questionnaires and their typical content, a conscious effort was
made not to restrictively impose those assumptions on par-
ticipants, facilitating their inductive contributions.
The interviews were audio recorded, transcribed verbatim, ano-
nymized, and analyzed with a modified, iterative framework
analysis to generate themes.12 Framework analysis is a flexible
approach, considered independent from any particular theoreti-
cal, philosophical, or epistemologic stance.12 It was chosen
Glossary
CFA = confirmatory factor analysis; CMQM = Comprehensive Model of QoL in Muscular Dystrophy; DIF = differential item
functioning; DMD = Duchenne muscular dystrophy; EFA = exploratory factor analysis; GCS = Generic Core Scales; IRT =
item response theory; MSA = Mokken scale analysis; NHS = National Health Service; PedsQL = Pediatric Quality of Life
Inventory; PPIE = patient and public involvement and engagement; PROM = patient-reported outcome measure; QoL =
quality of life; RMSEA = root mean square error of approximation.
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because it enables a combination of deductive (from a priori QoL
themes) and inductive (new themes from participants) analysis
and is commonly used in qualitative health care research, in-
cluding in projects developing PROMs from qualitative data.13,14
Coding was deductive (based on initial QoL themes cov-
ered in the topic guide) and inductive (emerging themes
from the data) and was conducted on hard copy transcripts
using the margins. Coding was split between the in-
terviewer (who coded all transcripts) and another member
of the research team (who secondary coded 50% of the
transcripts to enhance trustworthiness). Before coding, the
researchers familiarized themselves with the data by read-
ing and listening to the recordings of the transcripts being
analyzed.
After 2 adult and 2 child transcripts had been secondary
coded, the 2 researchers met to discuss their analysis and to
derive an initial working thematic framework. This working
framework was then applied to subsequent transcripts by the
Figure 1 Stages of Development of the DMD-QoL
DMD = Duchenne muscular dystrophy; PPIE = patient and
public involvement and engagement; PROM = patient-
reported outcome measure; QoL = quality of life.










7–9 10–14 15–19 20–29 30–39 ≥40
✓ ✓ ✓ 2 3 1 1
✗ ✓ ✓ 3 1
✗ ✗ ✓ 2 1
✗ ✗ ✗ 1 2 1
Total 2 6 3 4 2 1
Abbreviations: Lower limb function ✓/✗ = can/cannotwalk independentlywithout amobility device; gross upper limb function✓/✗ = can/cannot raise a hand to
mouth to eat/drink independently; respiratory function ✓/✗ = can/cannot breathe without any ventilator support throughout the day.
N = 18.
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lead researcher, with 5 of the remaining transcripts secondary
coded. Throughout coding, the researchers kept track of
proposed iterative modifications to the framework based on
the data. After all transcripts had been analyzed, the re-
searchers met again to discuss and agree on a final framework
for item generation.
The results of the analysis were discussed and refined with
stakeholders during a PPIE advisory meeting (with patients
and patients’ parents). Initial draft items for the DMD-QoL
were then generated from the themes by the research team, in
combination with advisory discussions with consultant NHS
clinicians (including consultants in pediatric neurology, adult
Table 2 Summary of the Rules Used for Item Selection Across all Stages
Stage 1: item generation Stage 2: initial item selection
1A. Reflects QoL in DMD 2A. Reapply rules from stage 1
At least 1 item per domain. 2B. Ensure comprehensibility
1B. Ease of completion Remove/revise if not understood as intended.
Reading level appropriate (≥7 y). 2C. Ensure relevance
Avoid double barrel (e.g., anxiety and depression). Remove/revise if not considered relevant to DMD.
Avoid double negatives. 2D. Ensure comprehensiveness
Avoid jargon and colloquialisms (e.g., “felt blue”). Consider participant suggestions for missing items.
Avoid making items too long. Add item if it does not conflict with rules from Stage 1.
Avoid overly personal items (e.g., sexual activity). Add item if it does not increase overlapping items.
Avoid items not relevant to all (e.g., work). 2E. Reduce redundancy/overlap
Avoid ethically inappropriate questions. Choose preferred item from cognitive debriefing.
Avoid questions on external knowledge. Retain similar items if people do distinguish them.
1C. Not value laden Stage 3: final item selection
Avoid value-laden statements (i.e., “X is good”). 3A. Reapply rules from stage 1
Avoid items not predictive of good/bad QoL for all. 3B. Reflects QoL in DMD
1D. Interpersonal and intertemporal comparison At least 1 item per original domain.
Avoid temporal comparisons (e.g., “as usual”). At least 3 items per CMQM domain.
Avoid personal comparisons (e.g., “as my peers”). 3C. Psychometric performance
Avoid expectations (e.g., “things will get better”). Good-fitting model (EFA/CFA).
Choose items focused on the current situation. No cross-loadings (EFA/CFA).
Avoid trait items (e.g., “I have a bad temper”). Minimize problems with local independence (MSA).
1E. Psychometric performance Minimize problems with monotonicity (MSA).
Avoid items likely to suffer from DIF. Minimize problems with IIO (MSA).
Items cover a range of severity within DMD QoL. Minimize problems with item fit (IRT).
Avoid items for which more is not always better. Minimize disordered thresholds (IRT).
Captures domain of interest. Minimize DIF (IRT).
1F. Suitable for valuation 3D. Acceptable to stakeholders
Can be traded off. Consider removal if disliked by patients in PPIE.
Amenable to change through health interventions. 3E. Reduce redundancy/overlap
1G. Suitable for translation Competing items retain more general vs specific.
Abbreviations: CMQM=ComprehensiveModel of QoL inMuscular Dystrophy; DIF = differential item functioning; DMD =Duchennemuscular dystrophy; EFA/
CFA = exploratory/confirmatory factor analysis; IRT = Item response theory; MSA = Mokken scale analysis; PPIE = patient and public involvement and
engagement; QoL = quality of life.
Stage 1 rules adapted from the EQALY project.15
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neuromuscular disorders, and physiotherapy). Draft items
were developed following a set of rules developed in previous
projects while bearing in mind the scope of the current
measure (table 2).15 This included consideration of the
minimum age of the target population (7 years) and wording
items to be reading level appropriate.
Stage 2: Initial Item Selection
To assess the content validity of the draft DMD-QoL and to
reduce redundant items, draft items were shown to patients (n =
10), patients’ parents (n = 10), and clinicians (n = 8) for their
feedback. This sample size was based on a recommended sample
size of ≈30 participants for pretesting questionnaires.16 All par-
ticipants were based in the United Kingdom. The parents were
predominantly mothers (70%) 30 to 59 years of age. Likewise,
the clinicians interviewed were largely female (75%) between 40
and 59 years of age. Background characteristics for the patients
are given in table 3. Eligible parents and clinicians, who either
were a parent of someone with DMD or worked with people
with DMD, were opportunity sampled via Duchenne UK. The
patients were all participants in the stage 1 qualitative study, so
this provided an opportunity for “member checking” our ana-
lytical decisions.5,17
In a face-to-face or online interview, participants provided
feedback on the 43 draft items, which were grouped (color-
coded) by theorized qualitative theme. The participants re-
ceived the set of items in advance. These cognitive debriefing
interviews took place between February 2019 and April 2019.
They were not recorded, but anonymized notes were taken.
The exercise was designed to assess relevance (are the items,
response options, and recall period appropriate?), compre-
hensiveness (are all key concepts included?), and compre-
hensibility (are the PROM instructions, items, and response
options understood as intended?).18 In the case of over-
lapping items (e.g., “I felt sad” vs “I felt happy”), participants
were asked their preference. A topic guide (available online:
doi.org/10.15131/shef.data.12942998.v1, file B) was pro-
duced to help facilitate this cognitive debriefing exercise.
Stage 3: Final Item Selection and
Psychometric Survey
Tomake a final item selection for the DMD-QoL, 3 sources of
data were used, combined with a set of item selection rules
(table 2). First, a stakeholder exercise had 3 groups (PPIE
patient/parent representatives, clinicians, or health economist
researchers) sorting the items within each qualitative domain
into 1 of 3 outcomes. A traffic-light system was used (red =
should not be in the final measure, amber = undecided or
overlaps with another item, green = should be in the final
measure), with the requirement that at least 1 item was in the
green category per domain. Second, the items underwent an
initial pretranslatability assessment by Oxford University In-
novation Clinical Outcomes (including Afrikaans, French,
German, Hebrew, Hindi, Russian, Simplified Chinese, and
Spanish) to highlight any translatability concerns. Third, a
Table 3 Patient Background Characteristics for Stage 1














Assistance needed to walk
Able towalk for distances >10min
without a mobility device
2 2
Able towalk for distances <10min
without a mobility device
5 2
Always uses a mobility device 11 6
Assistance needed to transfer (from




Can transfer with some
support
1 0
Needs a person or lifting device to
transfer
11 6
Assistance needed to eat
Can raise own hand to mouth
with food or drink
independently
9 6
Can raise own hand to mouth
with food or drink with some
support
2 0
Needs another person to bring
food or drink to mouth
7 4
Assistance needed to breathe
Does not use a ventilator at all 14 8
Uses a ventilator at night 1 0
Uses a ventilator during the day
and night
3 2
Use of steroid and heart
medication
Does not take steroid or heart
medication
1 1
Takes steroid medication 3 3
Takes heart medication 3 1
Takes steroid and heart
medication
11 5
Total, n 18 10
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psychometric survey was conducted with >100 UK DMD
patients and caregivers.
Psychometric Survey
Theminimum sample size for the psychometric survey was 100
participants, given that numbers above this tend to provide
more stable estimates in item response theory (IRT) analy-
ses.19 UK patients and parents were recruited between August
2019 and January 2020 via closed recruitment channels by the
participating NHS sites and charities and support groups (in-
cluding Duchenne UK, Muscular Dystrophy UK, and DMD
Pathfinders). Eligibility criterion was a self-disclosed diagnosis
of DMD (or to be responding on behalf of someone with a
diagnosis of DMD). Participants could request a £5 Amazon
e-voucher for taking part. To facilitate inclusivity, the survey
could be completed by self-report (by a patient), assisted self-
report (someone helped the patient complete the survey), or
proxy (someone answered on behalf of the patient). It was
made clear that only 1 response was allowed per patient. The
survey was completed online and hosted on Qualtrics.
Participants completed several background and clinical
questions on physical functioning, including the Brooke scale,20
medication and treatment, and age. They then completed, in a
fixed order, a 27-item draft DMD-QoL questionnaire (self-
report or proxy), EQ-5D with age-appropriate variants (either
EQ-5D-5L or EQ-5D-Y,8,21 self-report or proxy), and the Pe-
diatric Quality of Life Inventory (PedsQL)Generic Core Scales
(GCS)22 with age-appropriate variants: PedsQL GCS young
child (ages 5–7 years), proxy only; and PedsQL GCS child
(ages 8–12 years), adolescent (ages 13–17 years), young adult
(ages 18–25 years), and adult (ages ≥26 years), all self-report or
proxy. A copy of the survey outline is available online (doi.org/
10.15131/shef.data.12942998.v1, file C). The survey took a
median of 11.7 minutes to complete.
Psychometric analyses conducted on the items included
Mokken scale analysis (MSA), IRT analyses using a rating scale
model, and factor analyses. MSA was used to examine for vio-
lations of homogeneity of scale (H < 0.30) and significant vi-
olations of local independence, monotonicity, and invariant
item ordering.23 IRT was used to explore violations of item fit
using mean squares (expected range 0.6–1.4)23 and ordered
thresholds. Items were also assessed for differential item func-
tioning (DIF) based on report method (self-report or assisted
self-report vs proxy) and adult (>15 years) or child (7–15 years)
status using a default, recommended α level of 0.01.24 Sixteen
years of age was used as the cutoff point for adulthood in the
current research because it is where children begin to transition
to adult services in the United Kingdom. Analyses were con-
ducted independently on unidimensional subscales (wherever
possible) and, when not possible, on the total QoL scale.
Initial confirmatory factor analyses (CFAs) were conducted
according to underlying theory. The qualitative themeswere too
numerous to fit to the data, and some of the themes had <3
indicators. Accordingly, to facilitate the CFA, items were
mapped to the Comprehensive Model of QoL in Muscular
Dystrophy (CMQM).2 This model has 3 domains: physical,
psychological, and social. Details of this mapping are available
online (doi.org/10.15131/shef.data.12942998.v1, file D). Given
that the 3 QoL domains were assumed to be correlated and a
total score was to be generated for the PROM, a hierarchical
CFA was modeled, with items loading onto the 3 subscales and
the 3 subscales loading onto an overall QoL factor. A unidi-
mensional CFA was also modeled for comparison. Follow-up
exploratory factor analyses (EFAs) were conducted on a base-
line 1-factor and 2- and 3-factor solutions (as suggested as the
potential optimal number of factors by factor diagnostics, in-
cluding very simple structure,25 the Velicer minimum average
partial test,26 and parallel analysis) on the polychoric correlation
matrix using oblimin rotation due to poor CFA fit.
Scoring and Relationship With Other Variables
After the final item selection, scores on the DMD-QoL were
calculated and correlated against known sociodemographic
and clinical characteristics, EQ-5D score, and PedsQL GCS
score. The PedsQL GCS and its subscales were scored in a
summative way, taking the mean across items within each
scale. Utility scores for the EQ-5D-Y were generated with the
3L value set,27 while the EQ-5D-5L was scored with the
recommended cross-walk algorithm.28 EQ-5D-Y and EQ-5D-
5L responses were combined in the analyses because the
utility scores are generated using the same value set.
All analyses were conducted in R x64 3.6.1 (R Foundation for
Statistical Computing, Vienna, Austria)29 with the DescTools,30
eRm,31 lavaan,32 lordif,24 mokken,33 and psych packages.34
Data Availability
Anonymized data supporting the results of the psychometric
survey are available online (doi.org/10.15131/shef.data.
12942776.v1).
Results
Stage 1: Item Generation
Seven higher-order themes were extracted from the qualita-
tive data, of which 6 were directly relevant to QoL and 1
(health care and support) was deemed as a process attribute
(relating to treatment and care), rather than QoL. The QoL
themes were physical aspects, social relationships, autonomy
and independence, identity, feelings and emotions, and daily
activities. Example quotes for these themes are available
online (doi.org/10.15131/shef.data.12942998.v1, file I). A
total of 43 draft items were generated for the DMD-QoL,
which mapped onto these 6 themes. The full list of draft items
and how they mapped onto the qualitative themes is available
online (doi.org/10.15131/shef.data.12942998.v1, file E).
These draft items intentionally included multiple questions
on the same concept that differed linguistically for testing at
cognitive debriefing (e.g., “I felt sad” vs “I felt unhappy”). A
4-item response scale and 1-week recall period were selected
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on the basis of a review of existing measures, consideration of
the PROM age range, and PPIE and clinician input. Both of
these decisions were tested at cognitive debriefing. Language
for the response options (chosen to be on a frequency scale)
was generated with consideration of how often common re-
sponse option terms were used by participants during the
interviews (e.g., “sometimes” was used by all participants).
The response options selected were “never,” “sometimes,” “a
lot of the time,” and “all of the time.”
Stage 2: Initial Item Selection
Minor modifications were made to the PROM instructions
after a cognitive debriefing, including a “prefer not to disclose”
option (for use in the psychometric survey only) and the use
of “he” as opposed to “they” on the proxy version. While there
were mixed responses on a 4-point response scale and a
1-week recall period, the consensus was to leave these as they
were, particularly for a scale that was designed for young
children. Participants had mixed responses on item ordering
but preferred physical items first, before emotional items.
Because of some difficulties in understanding the questions in
participants <10 years old, we recommend that proxy report
be used for children between 7 and 10 years of age.
Regarding comprehensiveness of the PROM, participants
made a number of suggestions for additional content, of which
7 items were taken forward into the revised PROM, including
questions on breathing and eating. Twenty-three items were
dropped from the draft PROM (18 of these were redundant
or overlapping items), resulting in a revised 27-item version.
Summarized results from the cognitive debriefing and the
rationale for keeping and dropping individual items at this
stage are available in an item-tracking matrix online (available
online: doi.org/10.15131/shef.data.12942998.v1, file F).
Stage 3: Final Item Selection
Discussions within the patient and parent PPIE group revealed
clear preferences for a subset of the 27 items, with 14 coded as
green, 6 as amber, and 7 as red. The translatability assessment
suggested 1 problematic item (“I was happy with the people
around me”) and minor modifications to the instructions.
From a total of 225 people who accessed the psychometric
survey, 107 answered the DMD-QoL, and 118 dropped out of
the survey before answering the PROM. Of these 107, 5
people were excluded (2 people took >24 hours to complete
the survey, 2 gave clinically implausible answers for someone
with DMD according to published age-based norms and in
consultation with a clinician,35 and 1 responded to <80% of
the DMD-QoL items). This resulted in a valid sample for
analysis of 102. Overall 1.51% of data on the DMD-QoL were
missing (i.e., answered as “prefer not to disclose”) and were
median imputed to maximize data available for analysis.
Participant health and sociodemographic characteristics are
given in table 4. Thirty-seven responses were self- or assisted self-
reported, and 66 responses were proxy reported. Patients’ ages
ranged from 7 to 44 years (mean 15.77 years, SD 7.87 years). A
full distribution of responses on the 27 item set is available online
(doi.org/10.15131/shef.data.12942998.v1, file G).
The initial psychometrics on the full 27-item version revealed
a poor fit to the CMQMmodel: χ2(321) = 735.700, p < 0.001;
CFI = 0.699; root mean square error of approximation
(RMSEA) = 0.113 (0.102, 0.123), p < 0.001, or a unidimen-
sional model, χ2(324) = 893.40, p < 0.001; CFI = 0.549;
RMSEA = 0.146 (0.134, 0.157), p < 0.001. Correspondingly,
MSA revealed problems with homogeneity (4 items), local
independence (2 items), and invariant item ordering (6
items). The IRT analysis revealed problems with MSQ item
fit (4 items) and disordered thresholds (3 items). Full psy-
chometric results are available online (doi.org/10.15131/
shef.data.12942998.v1, file D).
To move toward a parsimonious measure (reducing overlap
and patient burden), the following rules were applied: an item
disliked by patients in the PPIE group was a candidate for
removal; items needed to be amenable to change via health care
intervention; more general items were preferred over specific
items; and at least 1 item was to be retained per original
qualitative domain and at least 3 items were to be retained per
CMQM domain. This resulted in a reduction from 27 items to
15 items. Decisions on which items were dropped/retained and
reasons why are in an item-trackingmatrix available online (doi.
org/10.15131/shef.data.12942998.v1, file H).
Analysis of the 15 items revealed a marginal improvement in
fit for the 3-domain CMQM model, χ2(87) = 190.33, p <
0.001; CFI = 0.790; RMSEA = 0.108 (0.087, 0.129), p <
0.001, but still not within acceptable levels. Problems were
also detected in the MSA and IRT. Accordingly, 1-factor,
2-factor, and 3-factor EFAs were conducted to help revise the
model (doi.org/10.15131/shef.data.12942998.v1, file D).
The EFA suggested an alternative latent structure for some of
the items, which also made theoretical sense. As a result, the
measurement model was revised, with 3 items (“I was in pain,”
“I felt tired,” and “I found it hard to talk to people”) reallo-
cated to the psychological theme, 2 items (“I found it hard to
get around” and “I could take part in the things I wanted to”)
moved to the social (participation) theme, and 1 item (“I felt
left out”) dropped due to cross-loading (>0.3) on the EFA.
This resulted in a 14-item PROM across 3 domains.
Psychometrics on the final 14-item PROM revealed a well-
fitting (albeit not confirmatory) 3 domain hierarchical model,
χ2(74) = 81.91, p = 0.247; CFI = 0.982; RMSEA = 0.032
(0.000, 0.067), p = 0.761, which fit better than a unidimen-
sional model, χ2(77) = 197.75, p < 0.001; CFI = 0.727;
RMSEA = 0.124 (0.103, 0.145), p < 0.001. The resultant
conceptual model for the DMD-QoL is presented in figure 2.
No problems were detected in MSA. Some minor problems
remained in MSQ item fit (4 items) at the 0.6 to 1.4 threshold
(but none so large as to degrade the measurement system36),
and the physical functioning subscale had disordered
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Table 4 Health and Sociodemographic Characteristics for the Stage 3 Psychometric Survey Sample
Which of the following can you do independently (without any
help)? Yes, n
Yes (partially or
with help), n No, n NA, n
Rise from lying on the floor to stand 2 27 69 4
Stand up from a chair 13 30 59 0
Stay standing for 3 s 37 12 3 0
Climb 4 stairs 7 28 67 0
Transfer from a bed to a chair 33 15 54 0
Walk/run for 10 m Run Run/walk Walk No
13 14 16 59
Brooke score 1 2 3 4 5 6
56 4 13 4 14 9
Medication use Yes No, but I used to No, I never have
Steroids 68 17 17
Heart medication 62 3 37
Treatments Yes No
Treatment for weaker bones 33 69
Spinal fusion surgery 16 86
Feeding tube 6 96
Ventilation Yes, day and night Yes, night No
11 12 79
Comorbid conditions ASD AD(H)D OCD Learning disability None NA
21 6 4 23 61 2
QoL measure Minimum Maximum Mean SD
DMD-QoL total 9 41 27.77 6.23
DMD-QoL physical functioning 1 9 7.37 1.94
DMD-QoL social participation 0 9 4.46 2.15
DMD-QoL psychological impact 1 23 15.94 3.88
PedsQL GCS totala 11.96 84.78 45.07 14.98
PedsQL physical functioninga 3.13 90.63 26.41 22.12
PedsQL emotional functioninga 10 100 56.61 20.51
PedsQL social functioninga 10 90 48.52 19.57
PedsQL school/work functioninga 5 100 60.42 22.00
EQ-5D-Yb −0.594 0.814 0.309 0.401
EQ-5D-5Lc −0.268 0.850 0.200 0.270
EQ-5D combinedd −0.594 0.850 0.206 0.346
Abbreviations: AD(H)D = attention-deficit (hyperactivity) disorder; ASD = autism spectrum disorder; PedsQL GCS = Pediatric Quality of Life Inventory Generic
Core Scales; NA = missing data (answered as “prefer not to disclose”); OCD = obsessive compulsive disorder; QoL = quality of life.
Subscale scores not calculated for the EQ-5Das per standard practice. N = 102 (except as indicated: an =96, bn=26, cn= 31, dn =57). Full copies of the questions
used in the survey are included in supplementary file C (doi.org/10.15131/shef.data.12942998.v1).
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thresholds (but not when incorporated as a total scale), which
could potentially be remedied by reducing the response op-
tions to 3 for this subscale. No DIF was detected for reporting
method. While 2 of the subscales could not be assessed for DIF
(<4 items), 1 item in the psychological subscale (“I felt tired”)
displayed adult/child DIF, with children typically reporting
feeling more tired than adults. This is potentially explicable in
that children tend to be still mobile, but their weak musculature
results in extra effort, and they will experience fatigue as a result
of this.37 When considering the scale as a whole, 5 additional
items displayed potential adult/child DIF, 4 of which (“I found
it hard to get around,” “I found it hard to use my hands” “I
found it hard to eat,” and “I found it hard to breathe”) are due
to expected underlying differences in ability with age and thus
represent benign rather than adverse DIF.38The other item (“I
could take part in things with my friends”) displayed uniform
DIF, with children more likely to endorse this item than adults.
This suggests that it may be interpreted differently across age
groups but is limited by analysis of a multidimensional item set
with a relatively small sample size.39 Accordingly, no further
changes were considered justified at this stage in the absence of
further validation in an independent dataset.
Scoring and Relationship With Other Variables
Summative scores were calculated for the 3 DMD-QoL sub-
domains and the total scale score (supported by the hierar-
chical CFA), with 3 items reversed so that a higher score
represented a better QoL (3 = never, 0 = all the time). The
Cronbach α for the total DMD-QoL was 0.84, with α values of
0.76, 0.74, and 0.83 for the physical, social, and psychological
subscales, respectively. Summary scores for the QoLmeasures
are listed in table 4.
For the DMD-QoL, the average total score was the same for
adults (mean 27.6, SD 6.4) and children (mean 27.9, SD 6.2),
although this differed across the subscale scores. Adults scored
significantly lower on the physical subscale (mean 6.6, SD 2.2)
than children (mean 8.0, SD 1.5), t (71.38) = 3.45, p < 0.001.
Whereas adults scored significantly higher on the psycho-
logical subscale (mean 16.9, SD 3.5) than children (mean
15.2, SD 4.0), t (97.8) = 2.22, p = 0.029, on the social subscale,
scores for adults (mean 4.1, SD 2.3) and children (mean 4.7,
SD 2.0) did not significantly differ. Reported QoL was lowest
for assisted report (mean 26.7, SD 7.7), followed by proxy
report (mean 27.4, SD 5.5) and self-report (mean 30.0, SD
7.0), on the DMD-QoL. None of these differences were sta-
tistically significant.
EQ-5D utility score was significantly higher in children (mean
0.309, SD 0.401) than adults (mean 0.120, SD 0.270), t
(42.55) = 2.04, p = 0.047, although this is generated with
different measures. As with the DMD-QoL, lowest utilities
were reported for the assisted report (mean −0.019, SD
0.091). However, utilities were lower in the self-report (mean
0.175, SD 0.286) than proxy report (mean 0.279, SD 0.392)
group. The differences between groups were significant at the
Figure 2 Conceptual Model of the DMD-QoL
Standardized factor loadings shown (N = 102). DMD = Duchenne muscular dystrophy; QoL = quality of life.
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10% level, F2,54 = 2.611, p = 0.083. Finally, for the PedsQL
GCS total score, there was a nonsignificant trend for QoL to
be lower in children (mean 44.1, SD 16.7) than adults (mean
46.4, SD 12.3). Regarding reporting method, self-report had
the highest score (mean 50.3, SD 9.5), followed by assisted
(mean 43.9, SD 14.2), and proxy (mean 43.7, SD 16.3) report.
These differences were nonsignificant.
Pearson and point-biserial correlations between the QoL
PROMs and background measures are displayed in table 5.
The DMD-QoL total score had large significant positive
correlations with the PedsQL GCS total score and the EQ-5D
utility score, indicating convergent validity. Further conver-
gent validity for the DMD-QoL physical functioning subscale
was shown by its large significant negative correlation with age
Table 5 Pearson or Point-Biserial Correlations Between QoL Measures and Background Characteristics in Stage 3
Psychometric Survey
Variables (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12)
(1) DMD-QoL physical —
(2) DMD-QoL social 0.37a —
(3) DMD-QoL psychological 0.25a 0.51a —
(4) DMD-QoL total 0.59a 0.78a 0.88a —
(5) EQ-5D-Y utility score 0.46a 0.52a 0.65a 0.68a —
(6) EQ-5D-5L utility score 0.60a 0.49a 0.22 0.48a NA —
(7) EQ-5D combined utility
score
0.54a 0.50a 0.40a 0.57a 1.00a 1.00a —
(8) PedsQL physical 0.34a 0.30a 0.20a 0.33a 0.46a 0.21 0.41a —
(9) PedsQL emotional 0.15 0.45a 0.76a 0.67a 0.60a 0.15 0.30a 0.25a —
(10) PedsQL social 0.04 0.50a 0.65a 0.58a 0.49a 0.24 0.25b 0.24a 0.50a —
(11) PedsQL school/work −0.05 0.36a 0.46a 0.39a 0.54a 0.12 0.21 0.11 0.52a 0.55a —
(12) PedsQL total 0.22a 0.55a 0.66a 0.66a 0.66a 0.31 0.48a 0.69a 0.74a 0.73a 0.69a —
(13) Age −0.52a −0.20a 0.09 −0.17b −0.47a −0.39a −0.43a −0.36a 0.03 0.20b 0.37a 0.00
(14) Can rise from floor 0.33a 0.27a 0.07 0.24a 0.56a 0.46a 0.57a 0.44a 0.18b 0.10 −0.08 0.29a
(15) Can stand from chair 0.44a 0.32a 0.04 0.27a 0.72a 0.61a 0.67a 0.43a 0.04 0.03 −0.11 0.21a
(16) Can stay standing 0.48a 0.25a −0.02 0.22a 0.58a 0.66a 0.64a 0.27a −0.01 −0.04 −0.15 0.09
(17) Can walk/run 10 m 0.41a 0.28a 0.07 0.27a 0.74a 0.76a 0.70a 0.43a −0.01 0.03 −0.10 0.20b
(18) Can climb 4 stairs 0.40a 0.29a 0.07 0.27a 0.70a 0.61a 0.69a 0.48a 0.07 0.07 −0.07 0.27a
(19) Can transfer bed to chair 0.49a 0.25a 0.03 0.26a 0.72a 0.62a 0.69a 0.32a 0.02 −0.01 −0.11 0.14
(20) Brooke score −0.75a −0.26a 0.04 −0.30a −0.51a −0.60a −0.56a −0.24a 0.07 0.18b 0.23a 0.01
(21) Takes steroids 0.48a 0.12 −0.10 0.13 −0.01 0.47a 0.28a 0.10 −0.06 −0.20a −0.20b −0.08
(22) Takes heart medication −0.19b −0.07 0.05 −0.05 −0.13 −0.17 −0.24b −0.38a 0.05 0.02 0.11 −0.15
(23) Had bone treatment 0.09 0.15 −0.06 0.05 −0.44a 0.39a −0.07 −0.04 0.08 −0.04 0.03 0.01
(24) Had spinal fusion −0.53a −0.13 0.07 −0.17b NA −0.49a −0.38a −0.07 0.02 0.14 0.22a 0.06
(25) Uses electric wheelchair −0.47a −0.22a −0.02 −0.23a −0.58a −0.44a −0.58a −0.32a 0.03 −0.03 0.16 −0.12
(26) Uses ventilation −0.51a −0.15 0.06 −0.18b NA −0.49a −0.38a −0.26a 0.09 0.02 0.25a −0.03
(27) Has a feeding tube −0.39a −0.09 −0.02 −0.17 NA −0.29 −0.24b −0.19b −0.04 0.05 0.09 −0.06
(28) Has a comorbid condition 0.13 −0.06 −0.29a −0.16 −0.39b 0.21 −0.09 0.03 −0.25a −0.33a −0.41a −0.30a
Abbreviations: DMD = Duchenne muscular dystrophy; NA = no variation in at least one of the variables; PedsQL = Pediatric Quality of Life Inventory; QoL =
quality of life.
N = 102. Correlations use pairwise complete observations. Full copies of the questions used in the survey are available online (doi.org/10.15131/shef.data.
12942998.v1, file C).
a p < .05.
b
p < .10.
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and association with all other physical functioning back-
ground questions such as a large significant negative re-
lationship with the Brooke score. The DMD-QoL social
participation subscale had smaller significant correlations with
the physical functioning questions, as would be expected, but
not questions on medication, demonstrating some discrimi-
nant validity. Finally, the DMD-QoL psychological subscale
had a small significant negative correlation with having a
comorbid condition such as autistic spectrum disorder.
Discussion
Our primary objective was to develop a new QoL PROM for
use in boys and men with DMD (age ≥7 years) and to assess
its preliminary psychometric properties. The DMD-QoL is a
14-item measure with self-report (age ≥10 years) and proxy
(age ≥7 years) forms. The measure has a hierarchical
3-domain structure, with physical, social, and psychological
subdomains, and a superordinate QoL factor. The DMD-QoL
uses a summative scoring system for these domains. The
DMD-QoL has evidenced content validity (from stages 1 and
2 of this developmental work) and preliminary good psy-
chometric properties (with no problems in MSA and only
minor problems observed with item fit, disordered thresholds,
and DIF). The DMD-QoL is available for use from the li-
censors, Oxford University Innovation Clinical Outcomes.
The DMD-QoL development represents several successes,
including the realization of rigorous PROM development in
a rare condition (dealing with small numbers of patients), a
high degree of PPIE and clinician input, and the inclusion of
iterative qualitative work, which has resulted in a PROM
with evident content validity. The DMD-QoL is a PROM
designed for use across the life course, which has advantages
in being able to compare differences in QoL across DMD
progression on a common scale. The PROM is intentionally
short (14 item) to minimize patient burden (which is po-
tentially high in DMD)2,40 and to facilitate subsequent
transition to a preference-based measure.41 The DMD-QoL
and its preference-based variant will have benefit in
informing resource allocation decisions for health technol-
ogies (based on their effect on QoL) and may have potential
benefit in clinic as a tool to facilitate conversations and po-
tentially to inform care and treatment decisions.
Despite its strengths, there are several apparent limitations of
the PROM in its current form, which may be addressed in
future work. First, the DMD-QoL was designed to be suffi-
ciently comprehensive to assess aspects of QoL important to
people with DMD while not being too burdensome. This
means that the PROM may not be exhaustive and that certain
aspects of QoL such as sexual relationships and end-of-life
issues, which may be important to adults with DMD,42,43 were
considered inappropriate to be included in a questionnaire to
be used from childhood. Nevertheless, future work could
consider “bolt-on” questions to the DMD-QoL for adults.
Second, while we provide evidence here for the content validity
of the scale and some initial evidence for its construct validity,
further work is required to assess the PROM for its psychometric
performance in an independent sample, including, for example,
test-retest reliability and responsiveness.44 Because the un-
derlying latent structure of the measure was adjusted with the
use of the current dataset, the model requires confirmation
(validation) on an independent dataset. Relatedly, given the
relatively small sample size, self-report and proxy report re-
sponses were combined in the psychometric analyses of the
items and to inform item selection. While we believe this is
defensible because the 2 variants were hypothesized to share the
same measurement model and no DIF was detected as a func-
tion of reporting method, future confirmatory work may con-
sider testing the self-report and proxy variants independently in
larger, targeted samples. This is particularly the case for elements
of QoL that are more difficult to observe such as in the psy-
chological subscale.6
Third, the PROM was developed for use in the United King-
dom. The initial translatability assessment of the PROM looks
promising, but it is not yet known whether the PROM will
perform well in other countries and cultures. Fourth, the de-
velopment of the DMD-QoL potentially suffers from selection
biases in recruitment. Frequently, opportunity samples were
used, and there is a need to further validate the measure in an
independent sample with broader characteristics (e.g., in those
unaffiliated with Duchenne UK; recruitment and participation
in clinic rather than on an online survey). It is not yet known
whether the validity of the PROM generalizes to the full
population of people with DMD in the United Kingdom or
indeed internationally, and further research is needed. This
includes research in specific clinical groups such as those with
comorbid conditions resulting in relatively lower cognitive
function. Furthermore, limited background data were collected
on the parents of patients with DMD taking part in the re-
search. For example, we did not collect data on whether par-
ticipating mothers were manifesting carriers. Characteristics
such as these may have influenced responses, but this is not
testable in the current data.
The 14-item DMD-QoL was designed in collaboration with,
and for use in, the Duchenne community to have good con-
tent validity relative to existing QoL PROMs.5 Initial analyses
suggest that DMD-QoL performs well in people with DMD
(and their caregivers). However, taking into account the
aforementioned limitations, the DMD-QoL requires further
independent validation and needs to be compared for its
performance against alternative QoL instruments. In the next
stage of its development, the measure will be valued to gen-
erate a preference-based measure that can be used to generate
quality-adjusted life-years to inform resource allocation de-
cisions within health technology assessments.
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